OPTI-HER-HEART (SOLTI-1002)
Clinical Trial Program
A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin (Myocet®) plus paclitaxel, trastuzumab and pertuzumab in patients with operable HER2-positive breast cancer
Phase II
Status
Finished
Tumour subtype:
HER2+
Scenario
Neoadjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Joaquín Gavilá, MD, PhD (Instituto Valenciano de Oncología)
Sites
